Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)–Expressing CD4+ T cells
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Studies aimed at defining the association between host immune responses and human immunodeficiency virus (HIV) persistence during therapy are necessary to develop new strategies for cure. METHODS: We performed a comprehensive assessment of ultrasensitive plasma HIV RNA levels, cell-associated HIV RNA levels, proviral HIV DNA levels, and T cell immunophenotyping in a cohort of 190 subjects in whom HIV levels were suppressed by highly active antiretroviral therapy. RESULTS: The median CD4(+) T cell count was 523 cells/mm(3), and the median duration of viral suppression was 31 months. Cell-associated RNA and proviral DNA levels (but not ultrasensitive plasma HIV RNA levels) were positively correlated with frequencies of CD4(+) and CD8(+) T cells expressing markers of T-cell activation/dysfunction (CD38, HLA-DR, CCR5, and/or programmed cell death protein 1 [PD-1]) (P < .05). Having a low CD4(+) T-cell count despite receipt of virologically suppressive therapy was associated with high cell-associated RNA and proviral DNA levels (P < .01) and higher frequencies of CD4(+) T cells expressing CD38, HLA-DR, CCR5, and/or PD-1 (P < .0001). CONCLUSIONS: Cell-based measurements of viral persistence were consistently associated with markers of immune activation and the frequency of PD-1-expressing CD4(+) T cells. Treated patients with a low CD4(+) T-cell count had higher frequencies of PD-1-expressing CD4(+) T cells and cell-based measures of viral persistence, suggesting that HIV infection in these individuals may be more difficult to cure and may require unique interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“Expression of PD-1 causes impaired HIV-specific immunity [14, 17], and PD-1 CD4 T cells are highly Received 21 March 2012; accepted 30 July 2012; electronically published 22 October 2012.”
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680 · cited 2×
“surements in untreated individuals [13].”
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231 · cited 3×
“T-Cell Activation, T-Cell Dysfunction, and Viral Persistence in Low and High CD4 T-Cell States There is growing recognition that the peripheral CD4 T-cell count during long-term antiretroviral therapy is a major predictor of morbidity and mortality [26, 27].”
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
Wong, J. K., Hezareh, M., Günthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., & Richman, D. D. (1997) · Science · doi:10.1126/science.278.5341.1291 · Cited by 2,186 · cited 1×
“virus (HIV) persists indefinitely in plasma [1, 2], peripheral blood mononuclear cells (PBMCs) [3, 4], and tissues [5–7].”
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., et al. (1997) · Nature · doi:10.1038/387183a0 · Cited by 2,050 · cited 1×
“virus (HIV) persists indefinitely in plasma [1, 2], peripheral blood mononuclear cells (PBMCs) [3, 4], and tissues [5–7].”
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F. A., Yassine-Diab, B., Boucher, G., Boulassel, M.-R., Ghattas, G., Brenchley, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1972 · Cited by 1,722 · cited 11×
“The median duration of viral suppression during HAART was 31 months PD-1 Expression and HIV Persistence • JID 2013:208 (1 July) • 51 at E ast C arolina U niversity on July 9, 2015 http://jid.oxfordjournals.org/ D ow nloaded from (IQR, 14–66 months).”
InfluentialSiliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703 · cited 1×
“phenomenon, including the presence of long-lived latently infected CD4 T cells [8], ongoing cryptic viral replication [9, 10], ineffective HIV-specific responses [11], and persistent immune activation [12–15].”
. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
Kuller, L. H., Tracy, R., Belloso, W., Wit, S. D., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J., Neuhaus, J., Nixon, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050203 · Cited by 1,617 · cited 1×
“T-cell response has been associated with significant clinical consequences, including increased AIDS-related and non– AIDS-related morbidity and mortality [26, 27, 32, 33].”
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565 · cited 2×
“cells [13, 14] and, hence, to a relative inability to clear infected cells [15].”
Hunt, P. W., Martin, J. N., Sinclair, E., Bredt, B., Hagos, E., Lampiris, H., & Deeks, S. G. (2003) · The Journal of Infectious Diseases · doi:10.1086/374786 · Cited by 852
Self-citationLow-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., Kempf, D. J., Mellors, J. W., Coffin, J. M., & King, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800050105 · Cited by 638 · cited 1×
“virus (HIV) persists indefinitely in plasma [1, 2], peripheral blood mononuclear cells (PBMCs) [3, 4], and tissues [5–7].”
Palmer, S., Wiegand, A. P., Maldarelli, F., Bazmi, H., Mican, J. M., Polis, M., Dewar, R. L., Planta, A., Liu, S., Metcalf, J. A., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4531-4536.2003 · Cited by 604 · cited 1×
“derive the single-copy assay detection limit reported by others [18].”
Persistence of HIV in Gut‐Associated Lymphoid Tissue despite Long‐Term Antiretroviral Therapy
Chun, T., Nickle, D. C., Justement, J. S., Meyers, J. H., Roby, G., Hallahan, C. W., Kottilil, S., Moir, S., Mican, J. M., Mullins, J. I., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/527324 · Cited by 574
J Buzón, M., Massanella, M., Llibre, J. M., Esteve, A., Dahl, V., Puertas, M. C., Gatell, J. M., Domingo, P., Paredes, R., Sharkey, M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2111 · Cited by 551 · cited 1×
“phenomenon, including the presence of long-lived latently infected CD4 T cells [8], ongoing cryptic viral replication [9, 10], ineffective HIV-specific responses [11], and persistent immune activation [12–15].”
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy
Sigal, A., Kim, J. T., Balazs, A. B., Dekel, E., Mayo, A., Milo, R., & Baltimore, D. (2011) · Nature · doi:10.1038/nature10347 · Cited by 537 · cited 1×
“tissues could support isolated rounds of de novo infection [10, 16].”
Kelley, C. F., Kitchen, C. M. R., Hunt, P. W., Rodriguez, B., Hecht, F. M., Kitahata, M., Crane, H. M., Willig, J., Mugavero, M., Saag, M., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597093 · Cited by 407 · cited 1×
“A significant proportion of individuals are unable to achieve a normal CD4 T-cell count despite prolonged viral suppression with effective HAART (“immunologic nonresponders”) [31].”
Self-citationCD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
Baker, J. V., Peng, G., Rapkin, J., Abrams, D. I., Silverberg, M. J., MacArthur, R. D., Cavert, W. P., Henry, W. K., & Neaton, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb76 · Cited by 372 · cited 1×
“T-cell response has been associated with significant clinical consequences, including increased AIDS-related and non– AIDS-related morbidity and mortality [26, 27, 32, 33].”
Hunt, P. W., Martin, J. N., Sinclair, E., Epling, L., Teague, J., Jacobson, M. A., Tracy, R. P., Corey, L., & Deeks, S. G. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir060 · Cited by 344 · cited 1×
“The detrimental effects of having a low CD4 T-cell count despite receipt of suppressive HAART have been most readily seen among individuals with a CD4 T-cell count <350 cells/mm(3) [26]; indeed, this threshold has often been used by our group and others to define “immunologic failure,” or “incomplete CD4 T cell recove…”
Self-citationLederman, M. M., Calabrese, L., Funderburg, N. T., Clagett, B., Medvik, K., Bonilla, H., Gripshover, B., Salata, R. A., Taege, A., Lisgaris, M., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir507 · Cited by 328 · cited 3×
“To explore host-virus interactions in individuals with low versus high CD4 T-cell counts [29], we”
Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections
Zeng, M., Smith, A. J., Wietgrefe, S. W., Southern, P. J., Schacker, T. W., Reilly, C. S., Estes, J. D., Burton, G. F., Silvestri, G., Lifson, J. D., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45157 · Cited by 309 · cited 1×
“The degree of collagen deposition in lymphoid tissues has been shown to prevent access to T-cell survival factors such as interleukin 7 [36, 37] and has also been shown to predict the degree of treatment-mediated CD4 T-cell recovery [38, 39].”
Gandhi, R. T., Zheng, L., Bosch, R. J., Chan, E. S., Margolis, D. M., Read, S., Kallungal, B., Palmer, S., Medvik, K., Lederman, M. M., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000321 · Cited by 304 · cited 1×
“On the basis of the general inability of intensification studies to affect systemic inflammation [11, 34], we generally favor a model in which residual immune dysfunction is the most proximal cause of our”
Yukl, S. A., Gianella, S., Sinclair, E., Epling, L., Li, Q., Duan, L., Choi, A. L. M., Girling, V., Ho, T., Li, P., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/656722 · Cited by 296 · cited 1×
“virus (HIV) persists indefinitely in plasma [1, 2], peripheral blood mononuclear cells (PBMCs) [3, 4], and tissues [5–7].”
Self-citationYukl, S. A., Shergill, A. K., McQuaid, K., Gianella, S., Lampiris, H., Hare, C. B., Pandori, M., Sinclair, E., Günthard, H. F., Fischer, M., et al. (2010) · AIDS · doi:10.1097/qad.0b013e32833ef7bb · Cited by 237 · cited 2×
“phenomenon, including the presence of long-lived latently infected CD4 T cells [8], ongoing cryptic viral replication [9, 10], ineffective HIV-specific responses [11], and persistent immune activation [12–15].”
Self-citationHatano, H., Delwart, E. L., Norris, P. J., Lee, T.-H., Dunn-Williams, J., Hunt, P. W., Hoh, R., Stramer, S. L., Linnen, J. M., McCune, J. M., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01763-08 · Cited by 208 · cited 2×
“A modified approach of previously published methods for PBMC extraction and TMA amplification of cellassociated hepatitis C virus was used [20, 21].”
Self-citationHatano, H., Hayes, T. L., Dahl, V., Sinclair, E., Lee, T.-H., Hoh, R., Lampiris, H., Hunt, P. W., Palmer, S., McCune, J. M., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq138 · Cited by 195 · cited 3×
“On the basis of the general inability of intensification studies to affect systemic inflammation [11, 34], we generally favor a model in which residual immune dysfunction is the most proximal cause of our”
Self-citationZeng, M., Southern, P. J., Reilly, C. S., Beilman, G. J., Chipman, J. G., Schacker, T. W., & Haase, A. T. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002437 · Cited by 182 · cited 1×
“The degree of collagen deposition in lymphoid tissues has been shown to prevent access to T-cell survival factors such as interleukin 7 [36, 37] and has also been shown to predict the degree of treatment-mediated CD4 T-cell recovery [38, 39].”
Chun, T.-W., Murray, D., Justement, J. S., Hallahan, C. W., Moir, S., Kovacs, C., & Fauci, A. S. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir208 · Cited by 165 · cited 1×
“been observed by other groups, using more-sensitive assays [30].”
Schacker, T. W., Little, S. J., Connick, E., Gebhard, K. H., Zhang, Z., Krieger, J. N., Pryor, J., Havlir, D. V., Wong, J. K., Richman, D. D., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315178 · Cited by 146 · cited 1×
“tive HAART may be a consequence of delayed initiation of effective antiretroviral therapy, and they argue for very early initiation of antiretroviral therapy [40–42].”
Schacker, T. W., Brenchley, J. M., Beilman, G. J., Reilly, C., Pambuccian, S. E., Taylor, J. H., Skarda, D. E., Larson, M. C., Douek, D. C., & Haase, A. T. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.13.5.556-560.2006 · Cited by 144 · cited 1×
“The degree of collagen deposition in lymphoid tissues has been shown to prevent access to T-cell survival factors such as interleukin 7 [36, 37] and has also been shown to predict the degree of treatment-mediated CD4 T-cell recovery [38, 39].”
Schacker, T. W., Reilly, C., Beilman, G. J., Taylor, J. H., Skarda, D. E., Krason, D. A., Larson, M. C., & Haase, A. T. (2005) · AIDS · doi:10.1097/01.aids.0000194801.51422.03 · Cited by 119 · cited 1×
“The degree of collagen deposition in lymphoid tissues has been shown to prevent access to T-cell survival factors such as interleukin 7 [36, 37] and has also been shown to predict the degree of treatment-mediated CD4 T-cell recovery [38, 39].”
Boulassel, M., Chomont, N., Pai, N. P., Gilmore, N. J., Sékaly, R., & Routy, J. (2011) · Journal of Clinical Virology · doi:10.1016/j.jcv.2011.09.018 · Cited by 105 · cited 1×
“tive HAART may be a consequence of delayed initiation of effective antiretroviral therapy, and they argue for very early initiation of antiretroviral therapy [40–42].”
Lee, T., Paglieroni, T. G., Utter, G. H., Chafets, D. M., Gosselin, R. C., Reed, W., Owings, J. T., Holland, P. V., & Busch, M. P. (2005) · Transfusion · doi:10.1111/j.1537-2995.2005.00201.x · Cited by 103 · cited 9×
“T-Cell Immunophenotyping PBMCs were isolated from whole blood, cryopreserved, and stored at the UCSF AIDS Specimen Bank.”
InfluentialSelf-citationAnton, P. A., Mitsuyasu, R. T., Deeks, S. G., Scadden, D. T., Wagner, B. K., Huang, C. A., Macken, C. A., Richman, D. D., Christopherson, C., Borellini, F., et al. (2003) · AIDS · doi:10.1097/00002030-200301030-00008 · Cited by 77 · cited 1×
“virus (HIV) persists indefinitely in plasma [1, 2], peripheral blood mononuclear cells (PBMCs) [3, 4], and tissues [5–7].”
Self-citationEvidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals
Hatano, H., Delwart, E., Norris, P. J., Lee, T., Neilands, T. B., Kelley, C. F., Hunt, P. W., Hoh, R., Linnen, J. M., Martin, J. N., et al. (2010) · AIDS · doi:10.1097/qad.0b013e32833dba03 · Cited by 71
Self-citationMoore, D. M., Hogg, R. S., Chan, K., TYNDALL, M. W., Yip, B., & Montaner, J. S. (2006) · AIDS · doi:10.1097/01.aids.0000196180.11293.9a · Cited by 56 · cited 2×
“T-Cell Activation, T-Cell Dysfunction, and Viral Persistence in Low and High CD4 T-Cell States There is growing recognition that the peripheral CD4 T-cell count during long-term antiretroviral therapy is a major predictor of morbidity and mortality [26, 27].”
Sinclair, E., Tan, Q. X., Sharp, M., Girling, V., Poon, C., Natta, M. L. V., Jabs, D. A., Inokuma, M. S., Maecker, H. T., Bredt, B. M., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/508997 · Cited by 36 · cited 9×
“T-Cell Immunophenotyping PBMCs were isolated from whole blood, cryopreserved, and stored at the UCSF AIDS Specimen Bank.”
InfluentialSelf-citation
Cited by
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063
Self-citationSystemic Effects of Inflammation on Health during Chronic HIV Infection
Deeks, S. G., Tracy, R., & Douek, D. C. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.001 · Cited by 868
Self-citationFletcher, C. V., Staskus, K., Wietgrefe, S. W., Rothenberger, M., Reilly, C., Chipman, J. G., Beilman, G. J., Khoruts, A., Thorkelson, A., Schmidt, T. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318249111 · Cited by 664
Serrano-Villar, S., Sainz, T., Lee, S. A., Hunt, P. W., Sinclair, E., Shacklett, B. L., Ferre, A. L., Hayes, T. L., Somsouk, M., Hsue, P. Y., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004078 · Cited by 611
“T cell immunophenotyping was performed on cryopreserved peripheral blood mononuclear cells (PBMC), in fresh lymph node mononuclear cells (LNMC) from inguinal biopsies obtained from HIVinfected volunteers under ART-mediated viral suppression, and in mucosal mononuclear cells (MMC) obtained from rectal biopsies in the m…”
MethodSelf-citationImmune checkpoint blockade in infectious diseases
Wykes, M. N., & Lewin, S. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.112 · Cited by 570
Metadata
- Authors
- Hatano, H., Jain, V., Hunt, P. W., Lee, T.-H., Sinclair, E., Do, T. D., Hoh, R., Martin, J. N., McCune, J. M., Hecht, F., Busch, M. P., & Deeks, S. G.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-22
- Volume
- 208
- Issue
- 1
- Pages
- 50-56
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2110558548
- Cited by
- 251
- References
- 36
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.